摘要
旨在获得褐黄血蜱重组蛋白(rHfFer1和rHfAV422)并评价其作为抗蜱疫苗的免疫保护效果。通过原核表达获得rHfFer1和rHfAV422,然后将22只新西兰兔随机分为3组(皂素对照组和两个免疫组),其中皂素对照组6只,两个免疫组各8只,所有兔均免疫两次,首免14 d后同等剂量进行二免,二免后一周感染幼蜱,根据蜱的饱血率和蜕皮率为指标评估抗蜱效果。结果显示,rHfFer1和rHfAV422免疫组的饱血率和蜕皮率与对照组均存在显著差异(P<0.05),计算得出rHfFer1和rHfAV422的抗蜱效果分别为68.06%和50.00%。研究结果表明,rHfFer1和rHfAV422可以作为抗蜱疫苗研发的候选抗原。
(Objective)This study aimed to obtain rHfFer1 and rHfAV422 of Haemaphysalis flava and evaluate their anti-tick vaccine efficacy.(Method)The rHfFer1 and rHfAV422 recombinant proteins of H.flava were obtained by prokaryotic expression and twenty-two rabbits were randomly divided into three groups(Quil-A saponin control group and two immunization groups),among them,there were six rabbits in the Quil-A saponin control group and eight rabbits in each of the two immunized groups.Fourteen days after the first immunization,the same dose was given for the second immunization,and the larvae infestation were conducted one week after the second immunization.Immune efficacy was evaluated according to the engorged and molting rate.(Result)The results showed that the engorged and molting rate of the rHfFer1 and rHfAV422 immunized groups were significantly different from those of the control group(P<0.05),the calculated anti-tick vaccine efficacy of rHfFer1 and rHfAV422 were 68.06%and 50.00%,respectively.(Conclusion)The result indicated that rHfFer1 and rHfAV422 could be used as candidate antigens for the development of anti-tick vaccines.
作者
陈玲
陈浩
岳婵娟
马锐
范雪阳
刘颂蕊
杨光友
CHEN Ling;CHEN Hao;YUE Chanjuan;MA Rui;FAN Xueyang;LIU Songrui;YANG Guangyou(Chengdu Research Base of Giant Panda Breeding,Sichuan Key Laboratory of Conservation Biology for Endangered Wildlife,Chengdu 610081,China;College of Veterinary Medicine,Sichuan Agricultural University,Chengdu 611130,China)
出处
《畜牧兽医学报》
CAS
CSCD
北大核心
2024年第2期688-697,共10页
ACTA VETERINARIA ET ZOOTECHNICA SINICA
基金
成都大熊猫繁育研究基地(四川省濒危野生动物保护生物学重点实验室)(2021KCPB-01)。
